Market revenue in 2023 | USD 3,037.7 million |
Market revenue in 2030 | USD 9,162.2 million |
Growth rate | 17.1% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Diagnostics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | Roche, Siemens Healthineers AG ADR, Janssen Pharmaceuticals, Illumina Inc, Quest Diagnostics Inc, 23andMe Holding Co Class A, NeoDiagnostix, International Business Machines Corp, Myriad Genetics Inc, Medtronic PLC, GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Dakota Software, Biogen Inc, Qiagen NV, ImmunityBio Inc Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to precision medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 74.3% in 2023. Horizon Databook has segmented the China precision medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
Government support and involvement in cross-border international collaborations for preventive & personalized medicine is expected to fuel market growth. Considering this factor, the Chinese government planned to make personalized medicine a part of its 5-Year Plan for 2016-2020 as it prioritizes genomics for better healthcare outcomes.
Similarly, the Chinese Academy of Sciences (CAS) allotted detailed application guidance for projects under the China Precision Medicine Initiative in 2016, which has to be funded with USD 9.2 billion by 2030. Wide applications of cell & gene therapies in China also play a key role in the progression of PM.
For instance, GE Healthcare developed three KUBio manufacturing facilities for Chinese biopharmaceutical companies in 2018, which expanded the company’s Flex Factory offerings in China to meet the manufacturing requirements of cell & gene therapies.
Horizon Databook provides a detailed overview of country-level data and insights on the China precision medicine market , including forecasts for subscribers. This country databook contains high-level insights into China precision medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account